Veru reports clinical data from the discontinued artest study of enobosarm, novel selective androgen receptor targeting agonist, in ar+ er+ her2- metastatic breast cancer

-- overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated population versus no responses in the standard of care active control arm. on average, enobosarm or active control was given in the 4 th line treatment in the metastatic setting which included a prior cdk 4/6 inhibitor combination-- --overall response rate was 20% for enobosarm monotherapy versus 0% for standard of care active control in patients who had ≤3 lines of prior endocrine therapy in the metastatic setting--
VERU Ratings Summary
VERU Quant Ranking